AB1315 Medication use among pregnant women with rheumatic diseases in korea based on the national health insurance service-national sample cohort. (12th June 2018)

• Record Type: Journal Article
• Authors: Chung, M.K.; Lee, J.; Ha, E.-H.; Shin, J.-Y.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1748
• Page End: 1749
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.5123
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Many rheumatic diseases (RD) predominantly affect women in their reproductive ages. Medication use during pregnancy is an important issue in women with RD since it may affect the health of both fetus and the mother. Objectives: This study aimed to characterise the status of medication dispensed for Korean women with RD in pre-gestational period and during pregnancy. Methods: Women aged between 20–44 years and diagnosed as RD and had delivery after the diagnosis of RD were identified from National Health Insurance Service-National Sample Cohort (NHIC-NSC) (2009–2013). Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylitis (AS) were included as RD. We analysed prevalence of RD related medication including disease-modifying antirheumatic drugs (DMARDs), NSAIDs, and corticosteroids (CSs) dispensed between the pre-gestational periods of 3 months before pregnancy until delivery. We also analysed prevalence of other medications and supplements which are commonly dispensed during pregnancy in women with RD and the age and sex matched controls. Results: There were 71 deliveries among 1059 women with RD. In RD pregnancies, 54.9% had taken at least 1 RD related medications. The prevalence of DMARDs dispensing during pregnancy was 23.9%, CSs 43.7%, and NSAIDs 38.0% in RD population. Although usage of antibiotics and medication for thyroid diseases during pregnancies were not different between the women with RD and the control, use of vitamin and iron supplements were significantly higher in the women with RD (38.0% vs 13.4%, p<0.0001). Conclusions: Medications are frequently required during pregnancies of women with RD. RD are a significant burden for pregnant women requiring increased number of medication use. References: [1] Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810. [2] Palmsten K, Simard JF, Chambers CD, Arkema EV. Medication use among pregnant women with systemic lupus erythematosus and general population comparators. Rheumatology (Oxford). 2017;56(4):561–9. Disclosure of Interest: None declared